DERIVATIVE LIABILITIES (Details) - USD ($)		3 Months Ended
	Mar. 31, 2022	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Derivative Liabilities [Line Items]
Conversion of Stock, Shares Converted (in Shares)	4,619
Sale of stock, percentage of ownership	19.90%
Milestone Payment		$ 10,000,000
Redemption term.		For the period ending upon the earlier of (i) 10 years after the closing of the IPO, or (ii) the conversion or redemption in full of the Series A Preferred Stock, the Company will pay to Knight a royalty equal to 3.5% of the Company’s net sales (the “Royalty”) on a quarterly basis, where “Net Sales” has the same meaning as in the Company’s license agreement with the U.S. Army for tafenoquine.
Royalty percentage		3.50%
(Loss) gain on change in fair value of derivative liabilities		$ (4,567)	$ 5,105
Valuation of contingent milestone payment, discount rate		13.00%		12.49%
Series A Non-Voting Convertible Preferred Stock [Member]
Derivative Liabilities [Line Items]
Designated shares (in Shares)	80,965	80,965